{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:19:25Z","timestamp":1783480765477,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Science Research Project of Hebei","award":["\uff0820260573\uff09"],"award-info":[{"award-number":["\uff0820260573\uff09"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15993-5","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T12:33:10Z","timestamp":1778329990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Osimertinib-induced interstitial lung disease insights from faers signal detection and network toxicology analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Shi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"3","key":"15993_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"15993_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00555-x","volume":"10","author":"LE Hendriks","year":"2024","unstructured":"Hendriks LE, Remon J, Faivre-Finn C, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2024;10(1):71. https:\/\/doi.org\/10.1038\/s41572-024-00555-x.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"15993_CR3","first-page":"2892","volume":"5","author":"A Midha","year":"2015","unstructured":"Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892\u2013911.","journal-title":"Am J Cancer Res"},{"issue":"7","key":"15993_CR4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1612674.","journal-title":"N Engl J Med"},{"issue":"2","key":"15993_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1713137.","journal-title":"N Engl J Med"},{"key":"15993_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00094","volume":"8","author":"A Bulbul","year":"2018","unstructured":"Bulbul A, Husain H. First-line treatment in EGFR mutant non-small cell lung cancer: is there a best option? Front Oncol. 2018;8:94. https:\/\/doi.org\/10.3389\/fonc.2018.00094.","journal-title":"Front Oncol"},{"issue":"1","key":"15993_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1056\/NEJMoa2510308","volume":"394","author":"PA J\u00e4nne","year":"2026","unstructured":"J\u00e4nne PA, Planchard D, Kobayashi K, et al. Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2026;394(1):27\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2510308.","journal-title":"N Engl J Med"},{"key":"15993_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1608733","volume":"16","author":"Z Lin","year":"2025","unstructured":"Lin Z, Wu L, Yu Y, et al. Case report: osimertinib-induced acute interstitial lung disease. Front Pharmacol. 2025;16:1608733. https:\/\/doi.org\/10.3389\/fphar.2025.1608733.","journal-title":"Front Pharmacol"},{"issue":"12","key":"15993_CR9","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.jtho.2020.08.025","volume":"15","author":"A Gemma","year":"2020","unstructured":"Gemma A, Kusumoto M, Sakai F, et al. Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with EGFR T790M-positive NSCLC treated with osimertinib in Japan. J Thorac Oncol. 2020;15(12):1893\u2013906. https:\/\/doi.org\/10.1016\/j.jtho.2020.08.025.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"15993_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jjco\/hyy179","volume":"49","author":"Y Ohe","year":"2019","unstructured":"Ohe Y, Imamura F, Nogami N, et al. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: flaura Japanese subset. Jpn J Clin Oncol. 2019;49(1):29\u201336. https:\/\/doi.org\/10.1093\/jjco\/hyy179.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"15993_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-23834-1","volume":"12","author":"Y Yin","year":"2022","unstructured":"Yin Y, Shu Y, Zhu J, et al. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib. Sci Rep. 2022;12(1):19555. https:\/\/doi.org\/10.1038\/s41598-022-23834-1.","journal-title":"Sci Rep"},{"issue":"2","key":"15993_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020792","volume":"22","author":"T Ohmori","year":"2021","unstructured":"Ohmori T, Yamaoka T, Ando K, et al. Molecular and clinical features of EGFR-TKI-associated lung injury. Int J Mol Sci. 2021;22(2):792. https:\/\/doi.org\/10.3390\/ijms22020792.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"15993_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"EvansSJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136. https:\/\/doi.org\/10.1002\/pds.677.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"15993_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"vanPuijenbroek EP, Bate A, Leufkens HGM, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310. https:\/\/doi.org\/10.1002\/pds.668.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"20","key":"15993_CR15","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s002280050466","volume":"17","author":"A Bate","year":"1998","unstructured":"BateA, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Stat Med. 1998;17(20):2313\u201331. https:\/\/doi.org\/10.1007\/s002280050466.","journal-title":"Stat Med"},{"issue":"3","key":"15993_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W DuMouchel","year":"1999","unstructured":"DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53(3):177\u201390.","journal-title":"Am Stat"},{"key":"15993_CR17","doi-asserted-by":"publisher","first-page":"1437884","DOI":"10.3389\/ftox.2024.1437884","volume":"6","author":"B Wyatt","year":"2024","unstructured":"Wyatt B, Davis AP, Wiegers TC, et al. Transforming environmental health datasets from CTD into chord diagrams to visualize molecular mechanisms. Front Toxicol. 2024;6:1437884. https:\/\/doi.org\/10.3389\/ftox.2024.1437884.","journal-title":"Front Toxicol"},{"issue":"2","key":"15993_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"BrownEG, Wood L, Wood S. The Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf. 1999;20(2):109\u201317. https:\/\/doi.org\/10.2165\/00002018-199920020-00002.","journal-title":"Drug Saf"},{"issue":"Web Server issu","key":"15993_CR19","doi-asserted-by":"publisher","first-page":"W32","DOI":"10.1093\/nar\/gku293","volume":"42","author":"D Gfeller","year":"2014","unstructured":"GfellerD, Grosdidier A, Wirth M, et al. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. Nucleic Acids Res. 2014;42(Web Server issue):W32\u20138. https:\/\/doi.org\/10.1093\/nar\/gku293.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"15993_CR20","doi-asserted-by":"publisher","first-page":"D1138","DOI":"10.1093\/nar\/gkaa891","volume":"49","author":"AP Davis","year":"2021","unstructured":"DavisAP, Grondin CJ, Johnson RJ, et al. Comparative Toxicogenomics Database (CTD): update 2021. Nucleic Acids Res. 2021;49(D1):D1138\u201343. https:\/\/doi.org\/10.1093\/nar\/gkaa891.","journal-title":"Nucleic Acids Res"},{"key":"15993_CR21","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/cpbi.5","volume":"54","author":"G Stelzer","year":"2016","unstructured":"StelzerG, Rosen N, Plaschkes I, et al. The GeneCards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinf. 2016;54:1301\u201313033. https:\/\/doi.org\/10.1002\/cpbi.5.","journal-title":"Curr Protoc Bioinf"},{"issue":"D1","key":"15993_CR22","doi-asserted-by":"publisher","first-page":"D833","DOI":"10.1093\/nar\/gkw943","volume":"45","author":"J Pi\u00f1ero","year":"2017","unstructured":"Pi\u00f1eroJ, Bravo \u00c0, Queralt-Rosinach N, et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Res. 2017;45(D1):D833\u20139. https:\/\/doi.org\/10.1093\/nar\/gkw943.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"15993_CR23","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607\u201313. https:\/\/doi.org\/10.1093\/nar\/gky1131","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"15993_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"DW Huang","year":"2009","unstructured":"Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44\u201357. https:\/\/doi.org\/10.1038\/nprot.2008.211.","journal-title":"Nat Protoc"},{"issue":"3","key":"15993_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.resinv.2024.03.007","volume":"62","author":"Y Fukuda","year":"2024","unstructured":"Fukuda Y, Uchida Y, Ando K, Manabe R, Tanaka A, Sagara H. Risk factors for interstitial lung disease in patients with non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors: a systematic review and meta-analysis. Respir Investig. 2024;62(3):481\u20137. https:\/\/doi.org\/10.1016\/j.resinv.2024.03.007.","journal-title":"Respir Investig"},{"issue":"8","key":"15993_CR26","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/jjco\/hyaa067","volume":"50","author":"Y Ohe","year":"2020","unstructured":"Ohe Y, Kato T, Sakai F, Kusumoto M, Endo M, Saito Y, et al. Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan. Jpn J Clin Oncol. 2020;50(8):909\u201319. https:\/\/doi.org\/10.1093\/jjco\/hyaa067.","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"15993_CR27","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.chest.2022.05.035","volume":"162","author":"Y Sato","year":"2022","unstructured":"Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, et al. Drug-related pneumonitis induced by osimertinib as first-line treatment for epidermal growth factor receptor mutation-positive non-small cell lung cancer: a real-world setting. Chest. 2022;162(5):1188\u201398. https:\/\/doi.org\/10.1016\/j.chest.2022.05.035.","journal-title":"Chest"},{"issue":"4","key":"15993_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100648","volume":"5","author":"MSC Li","year":"2024","unstructured":"Li MSC, Lee KWC, Mok KKS, et al. Brief report: risk of recurrent interstitial lung disease from osimertinib versus erlotinib rechallenge after symptomatic osimertinib-induced interstitial lung disease. JTO Clin Res Rep. 2024;5(4):100648. https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100648.","journal-title":"JTO Clin Res Rep"},{"issue":"1","key":"15993_CR29","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/j.cllc.2023.09.009","volume":"25","author":"F Kashizaki","year":"2024","unstructured":"Kashizaki F, Chen H, Miyasaka A, et al. Safety of readministration of EGFR-TKI after onset of interstitial lung disease in advanced EGFR-mutated NSCLC: a systematic review and meta-analysis. Clin Lung Cancer. 2024;25(1):e52\u20137. https:\/\/doi.org\/10.1016\/j.cllc.2023.09.009.","journal-title":"Clin Lung Cancer"},{"key":"15993_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1019451","volume":"13","author":"S Sang","year":"2022","unstructured":"Sang S, Sun C, Ding R, et al. Feiyanning formula modulates the molecular mechanism of osimertinib resistance in lung cancer by regulating the Wnt\/\u03b2-catenin pathway. Front Pharmacol. 2022;13:1019451. https:\/\/doi.org\/10.3389\/fphar.2022.1019451.","journal-title":"Front Pharmacol"},{"issue":"6","key":"15993_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cells11060986","volume":"11","author":"F Schramm","year":"2022","unstructured":"Schramm F, Schaefer L, Wygrecka M. EGFR signaling in lung fibrosis. Cells. 2022;11(6):986. https:\/\/doi.org\/10.3390\/cells11060986.","journal-title":"Cells"},{"issue":"1","key":"15993_CR32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1096\/fj.15-273953","volume":"30","author":"M Pedroza","year":"2016","unstructured":"Pedroza M, Le TT, Lewis K, et al. STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation. FASEB J. 2016;30(1):129\u201340. https:\/\/doi.org\/10.1096\/fj.15-273953.","journal-title":"FASEB J"},{"issue":"1","key":"15993_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.apsb.2021.07.023","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Hu K, Cai X, Yang B, He Q, Wang J, Weng Q. Targeting PI3K\/AKT signaling for treatment of idiopathic pulmonary fibrosis. Acta Pharm Sin B. 2022;12(1):18\u201332. https:\/\/doi.org\/10.1016\/j.apsb.2021.07.023.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"15993_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02118-w","volume":"4","author":"CJ Aros","year":"2021","unstructured":"Aros CJ, Pantoja CJ, Gomperts BN. Wnt signaling in lung development, regeneration, and disease progression. Commun Biol. 2021;4(1):601. https:\/\/doi.org\/10.1038\/s42003-021-02118-w.","journal-title":"Commun Biol"},{"key":"15993_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103095","volume":"62","author":"MS Eapen","year":"2020","unstructured":"Eapen MS, Sohal SS. WNT\/\u03b2-catenin pathway: a novel therapeutic target for attenuating airway remodelling and EMT in COPD. EBioMedicine. 2020;62:103095. https:\/\/doi.org\/10.1016\/j.ebiom.2020.103095.","journal-title":"EBioMedicine"},{"key":"15993_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3520581","volume":"2017","author":"J Shi","year":"2017","unstructured":"Shi J, Li F, Luo M, Wei J, Liu X. Distinct roles of Wnt\/\u03b2-catenin signaling in the pathogenesis of chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Mediators Inflamm. 2017;2017:3520581. https:\/\/doi.org\/10.1155\/2017\/3520581.","journal-title":"Mediators Inflamm"},{"issue":"1","key":"15993_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-95271-9","volume":"15","author":"H Ando","year":"2025","unstructured":"Ando H, Tsubouchi K, Yanagihara T, et al. Involvement of na\u00efve T cells in the pathogenesis of osimertinib-induced pneumonitis. Sci Rep. 2025;15(1):10545. https:\/\/doi.org\/10.1038\/s41598-025-95271-9.","journal-title":"Sci Rep"},{"issue":"10","key":"15993_CR38","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1096\/fj.201600502R","volume":"30","author":"D Bastakoty","year":"2016","unstructured":"Bastakoty D, Young PP. Wnt\/\u03b2-catenin pathway in tissue injury: roles in pathology and therapeutic opportunities for regeneration. FASEB J. 2016;30(10):3271\u201384. https:\/\/doi.org\/10.1096\/fj.201600502R.","journal-title":"FASEB J"},{"issue":"3","key":"15993_CR39","doi-asserted-by":"publisher","first-page":"C234","DOI":"10.1152\/ajpcell.00366.2013","volume":"307","author":"C Wang","year":"2014","unstructured":"Wang C, Zhu H, Sun Z, Xiang Z, Ge Y, Ni C, et al. Inhibition of Wnt\/\u03b2-catenin signaling promotes epithelial differentiation of mesenchymal stem cells and repairs bleomycin-induced lung injury. Am J Physiol Cell Physiol. 2014;307(3):C234\u201344. https:\/\/doi.org\/10.1152\/ajpcell.00366.2013.","journal-title":"Am J Physiol Cell Physiol"},{"key":"15993_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2022.114410","volume":"249","author":"Y Tian","year":"2023","unstructured":"Tian Y, Xia J, Yang G, Li C, Qi Y, Dai K, et al. A2aR inhibits fibrosis and the EMT process in silicosis by regulating Wnt\/\u03b2-catenin pathway. Ecotoxicol Environ Saf. 2023;249:114410. https:\/\/doi.org\/10.1016\/j.ecoenv.2022.114410.","journal-title":"Ecotoxicol Environ Saf"},{"issue":"1","key":"15993_CR41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.yexmp.2016.04.003","volume":"101","author":"X Chen","year":"2016","unstructured":"Chen X, Shi C, Meng X, Zhang K, Li X, Wang C, et al. Inhibition of Wnt\/\u03b2-catenin signaling suppresses bleomycin-induced pulmonary fibrosis by attenuating the expression of TGF-\u03b21 and FGF-2. Exp Mol Pathol. 2016;101(1):22\u201330. https:\/\/doi.org\/10.1016\/j.yexmp.2016.04.003.","journal-title":"Exp Mol Pathol"},{"issue":"12","key":"15993_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104002","volume":"9","author":"J Delahousse","year":"2024","unstructured":"DelahousseJ, Wagner AD, Borchmann S, et al. Sex differences in the pharmacokinetics of anticancer drugs: a systematic review. ESMO Open. 2024;9(12):104002. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104002.","journal-title":"ESMO Open"},{"key":"15993_CR43","doi-asserted-by":"publisher","first-page":"1419256","DOI":"10.3389\/fonc.2024.1419256","volume":"14","author":"Y Fujiwara","year":"2024","unstructured":"Fujiwara Y, Shimomura K, Yamaguchi T, et al. The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitor or immune checkpoint inhibitor in the presence and absence of vascular endothelial growth factor inhibitors: a systematic review. Front Oncol. 2024;14:1419256. https:\/\/doi.org\/10.3389\/fonc.2024.1419256.","journal-title":"Front Oncol"},{"issue":"5","key":"15993_CR44","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/14740338.2025.2494689","volume":"24","author":"J Yuan","year":"2025","unstructured":"Yuan J, Li Z, Ye M, Fu Z. A disproportionality analysis of interstitial lung disease associated with drug therapy in spontaneous adverse event reports. Expert Opin Drug Saf. 2025;24(5):593\u2013602. https:\/\/doi.org\/10.1080\/14740338.2025.2494689.","journal-title":"Expert Opin Drug Saf"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15993-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15993-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15993-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:04:07Z","timestamp":1783479847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15993-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15993"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15993-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study utilized publicly available data from the FDA Adverse Event Reporting System (FAERS) database. All data were anonymized and deidentified prior to access. Therefore, ethical approval and informed consent were not required in accordance with institutional and national research regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"824"}}